| pubmed-article:8669879 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0530993 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0010806 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0332255 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0040287 | lld:lifeskim |
| pubmed-article:8669879 | lifeskim:mentions | umls-concept:C0220927 | lld:lifeskim |
| pubmed-article:8669879 | pubmed:issue | 6B | lld:pubmed |
| pubmed-article:8669879 | pubmed:dateCreated | 1996-8-7 | lld:pubmed |
| pubmed-article:8669879 | pubmed:abstractText | A sensitive and relatively specific tumoral marker for lung epidermoid carcinomas could be used to identify patients likely to benefit from new therapeutic protocols. The cyfra 21-1 fragment of cytokeratin 19 has raised much hope in this regard amongst both technologists and clinicians. In a study of 195 subjects, we have shown by means of a serum assay that the usual cut-off value for this marker (3.3 ng/ml) can be lowered to 1.5 ng/ml without loss of specificity, and with an increase in sensitivity. There was a good correlation between serum marker level and tumor extension, but though cyfra 21-1 was not predictive of the suitability of a patient for surgery. A decrease of cyfra-21-1 was observed after complete resection of the tumor. There was no relation between serum assay results and immunohistochemical findings. | lld:pubmed |
| pubmed-article:8669879 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8669879 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8669879 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8669879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8669879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8669879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8669879 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8669879 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:LogeaisYY | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:DazordLL | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:BansardJ YJY | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:RameeM PMP | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:LanganayTT | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:CorbineauHH | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:BriensEE | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:QuillienVV | lld:pubmed |
| pubmed-article:8669879 | pubmed:author | pubmed-author:MeritteHH | lld:pubmed |
| pubmed-article:8669879 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8669879 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:8669879 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8669879 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8669879 | pubmed:pagination | 2857-63 | lld:pubmed |
| pubmed-article:8669879 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:meshHeading | pubmed-meshheading:8669879-... | lld:pubmed |
| pubmed-article:8669879 | pubmed:articleTitle | Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients. | lld:pubmed |
| pubmed-article:8669879 | pubmed:affiliation | Centre de Lutte Contre le Cancer Eugène Marquis, Département de Biologie Clinique et Expérimentale, Rennes, France. | lld:pubmed |
| pubmed-article:8669879 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8669879 | pubmed:publicationType | Comparative Study | lld:pubmed |
